Plasma functionalized PDMS microfluidic chips: towards point-of-care capture of circulating tumor cells

2011 ◽  
Vol 21 (24) ◽  
pp. 8841 ◽  
Author(s):  
Mahaveer D. Kurkuri ◽  
Fares Al-Ejeh ◽  
Jun Yan Shi ◽  
Dennis Palms ◽  
Clive Prestidge ◽  
...  
Author(s):  
Seth Jackson ◽  
Jeff Darabi ◽  
Joseph Schober

Abstract Significant research involving the isolation and detection of circulating tumor cells (CTCs) has become prevalent in the field of biomedicine. It plays a crucial role in the diagnosis and treatment of cancer and has made substantial strides in recent years. A major event in the timeline of cancer is metastasis, a set of occurrences where cells are shed from a cancerous site, then flow through the circulatory system and seed themselves throughout the body, forming secondary tumors. There are few observable symptoms in the early stages of metastasis and this fact severely limits clinical treatment. The fabrication and preliminary testing of a magnetophoretic bioseparation chip capable of isolating and detecting CTCs from peripheral blood, which can aid in early detection of metastases, is presented in this work. MCF7 breast cancer cells along with superparamagnetic microparticles, which are specifically coated with anti-EpCAM to bind to the cancer cells, are spiked into a blood sample. After the spiked blood sample is introduced into the biochip, a locally engineered magnetic field gradient captures the magnetically labeled cancer cells while the non-target cells are allowed to pass by. Once the target cells are isolated from the blood sample, flow cytometry is used to determine the recovery rate of the magnetophoretic device. The proposed device can operate at continuous flow rates magnitudes higher than other CTC isolation devices and is fabricated using much simpler methods which make it quite unique. These properties combined with greater than 80% recovery rates make the device quite favorable for economic point of care use in clinical applications.


2021 ◽  
Vol 171 ◽  
pp. 112718
Author(s):  
Yangfei Chen ◽  
Xuqi Chen ◽  
Mengna Li ◽  
Pengwei Fan ◽  
Bin Wang ◽  
...  

Sensors ◽  
2020 ◽  
Vol 20 (21) ◽  
pp. 6073
Author(s):  
Chunyang Lu ◽  
Jintao Han ◽  
Xiaoyi Sun ◽  
Gen Yang

Circulating tumor cells (CTCs) are tumor cells that escaped from the primary tumor or the metastasis into the blood and they play a major role in the initiation of metastasis and tumor recurrence. Thus, it is widely accepted that CTC is the main target of liquid biopsy. In the past few decades, the separation of CTC based on the electrochemical method has attracted widespread attention due to its convenience, rapidness, low cost, high sensitivity, and no need for complex instruments and equipment. At present, CTC detection is not widely used in the clinic due to various reasons. Point-of-care CTC detection provides us with a possibility, which is sensitive, fast, cheap, and easy to operate. More importantly, the testing instrument is small and portable, and the testing does not require specialized laboratories and specialized clinical examiners. In this review, we summarized the latest developments in the electrochemical-based CTC detection and point-of-care CTC detection, and discussed the challenges and possible trends.


2017 ◽  
Vol 1 (4) ◽  
pp. 389-402 ◽  
Author(s):  
Duanping Sun ◽  
Zuanguang Chen ◽  
Minhao Wu ◽  
Yuanqing Zhang

2017 ◽  
Vol 01 (01) ◽  
Author(s):  
Hongmei Chen ◽  
Baoshan Cao ◽  
Hongda Chen ◽  
Xiaoqing Lv ◽  
Lei Li

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chia-Heng Chu ◽  
Ruxiu Liu ◽  
Tevhide Ozkaya-Ahmadov ◽  
Brandi E. Swain ◽  
Mert Boya ◽  
...  

AbstractReliable and routine isolation of circulating tumor cells (CTCs) from peripheral blood would allow effective monitoring of the disease and guide the development of personalized treatments. Negative enrichment of CTCs by depleting normal blood cells ensures against a biased selection of a subpopulation and allows the assay to be applied on different tumor types. Here, we report an additively manufactured microfluidic device that can negatively enrich viable CTCs from clinically-relevant volumes of unmanipulated whole blood samples. Our device depletes nucleated blood cells based on their surface antigens and the smaller anucleated cells based on their size. Enriched CTCs are made available off the device in suspension making our technique compatible with standard immunocytochemical, molecular and functional assays. Our device could achieve a ~ 2.34-log depletion by capturing > 99.5% of white blood cells from 10 mL of whole blood while recovering > 90% of spiked tumor cells. Furthermore, we demonstrated the capability of the device to isolate CTCs from blood samples collected from patients (n = 15) with prostate and pancreatic cancers in a pilot study. A universal CTC assay that can differentiate tumor cells from normal blood cells with the specificity of clinically established membrane antigens yet require no label has the potential to enable routine blood-based tumor biopsies at the point-of-care.


Sign in / Sign up

Export Citation Format

Share Document